rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Marc Cobo

Principal Accounting Officer

Company insider

Files Form 4 as: Principal Accounting Officer, BridgeBio Oncology Therapeutics; SVP, Finance & CAO, Tricida.

Every Form 4 they filed

In numbers

Trades disclosed
11
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
2
Companies where not an officer
0
First trade
29 Jun 2020
Last trade
1 Oct 2026
Last filed
5 Oct 2026

Companies traded

Where they are an officer
BBOT BridgeBio Oncology TherapeuticsOfficer · Biotechnology · last 1 Oct 20260 buys · 0 sells
TricidaOfficer · last 10 Sep 20200 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
1 Oct 2026filed 5 Oct 2026BBOT BridgeBio Oncology TherapeuticsBiotechnologySEC FORM 4 Code F$496126 at $3.94filing
10 Sep 2026filed 14 Sep 2026BBOT BridgeBio Oncology TherapeuticsBiotechnologySEC FORM 4 Code A—9,038 at $0.00filing
10 Sep 2026filed 14 Sep 2026BBOT BridgeBio Oncology TherapeuticsBiotechnologySEC FORM 4 Code F$1,121203 at $5.52filing
10 Sep 2026filed 14 Sep 2026BBOT BridgeBio Oncology Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—43,700 at $0.00filing
10 Sep 2026filed 14 Sep 2026BBOT BridgeBio Oncology Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—43,700 at $0.00filing
10 Sep 2026filed 14 Sep 2026BBOT BridgeBio Oncology TherapeuticsBiotechnologySEC FORM 4 Code A—9,038 at $0.00filing
10 Sep 2026filed 14 Sep 2026BBOT BridgeBio Oncology TherapeuticsBiotechnologySEC FORM 4 Code F$1,121203 at $5.52filing
1 Jul 2026filed 6 Jul 2026BBOT BridgeBio Oncology TherapeuticsBiotechnologySEC FORM 4 Code F$975125 at $7.80filing
1 Jul 2026filed 6 Jul 2026BBOT BridgeBio Oncology TherapeuticsBiotechnologySEC FORM 4 Code F$975125 at $7.80filing
10 Sep 2020filed 14 Sep 2020TricidaSEC FORM 4 Code A—3,000 at $0.00filing
29 Jun 2020filed 1 Jul 2020Tricidaoption or derivativeSEC FORM 4 Code A—80,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Idan ElmelechCOO & Principal Financial Ofcr · COO & Principal Financial Ofcr at BridgeBio Oncology Therapeutics, filing Form 4 there in the last year
Pedro BeltranPresident and CEO · President and CEO at BridgeBio Oncology Therapeutics, filing Form 4 there in the last year
Yong BenChief Med & Dev Officer · Chief Med & Dev Officer at BridgeBio Oncology Therapeutics, filing Form 4 there in the last year
Bihua ChenDirector and 10% owner · Director and 10% owner at BridgeBio Oncology Therapeutics, filing Form 4 there in the last year
Frank McCormickDirector · Director at BridgeBio Oncology Therapeutics, filing Form 4 there in the last year